Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: Insights from a retrospective analysis Journal Article
| Authors: | Luttwak, E.; Robin, E. T.; Drill, E.; Boardman, A.; Caron, P.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Johnson, W.; Kumar, A.; Lue, J.; Noy, A.; Owens, C.; Palomba, M. L.; Steiner, R.; Stuver, R.; Torka, P.; Vardhana, S.; Zelenetz, A. D.; Salles, G.; Moskowitz, C. H.; Moskowitz, A. J. |
| Article Title: | Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: Insights from a retrospective analysis |
| Abstract: | T-cell/histiocyte-rich B-cell lymphoma (THRLBCL) is an uncommon variant of diffuse large B‐cell lymphoma (DLBCL). Historically, it is considered an aggressive variant with poorer outcomes; however, recent analyses suggest that outcomes may be better for patients treated in the rituximab era. We reviewed THRLBCL cases who were diagnosed in MSKCC from January 2000 to October 2019. A total of 67 patients were included with a median follow-up of 5.4 years (0.5–13.8). Frontline treatment included R-CHOP or R-CHOP-based treatment in 48%, R-EPOCH in 12%, R-CHOP/R-ICE in 33% and other palliative treatments in 7.5%. In the whole cohort, 5-year EFS and OS was 59% and 79%, respectively. In an analysis of patients who received therapy with R-CHOP-14 × 4 followed by ICE/R-ICE × 3 compared to patients who were treated with R-CHOP or R-CHOP based treatment, CR rates were 95% and 70%, respectively (p = 0.023). The R-CHOP/R-ICE regimen was also associated with higher event-free survival (5-year EFS of 80% vs 50%; p = 0.006) and overall survival (5-year OS of 100% vs 72%; p = 0013). Our study demonstrates better outcomes among patients with THRLBCL compared to historical data. Our findings suggest that treatment with a higher intensity regimen with noncross resistance, such as R-CHOP/R-ICE is reasonable approach for patients with newly diagnosed THRLBCL. © 2025 Memorial Sloan Kettering. Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | rituximab; r-chop; diffuse large b‐cell lymphoma; rchop/r-ice; t-cell/histiocyte-rich b-cell lymphoma |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 66 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Publication status: | Published |
| Date Published: | 2025-01-01 |
| Start Page: | 1276 |
| End Page: | 1283 |
| Language: | English |
| DOI: | 10.1080/10428194.2025.2465553 |
| PROVIDER: | scopus |
| PUBMED: | 40598813 |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work